Microbiota Composition May Predict Anti-Tnf Alpha Response in Spondyloarthritis Patients: an Exploratory Study

to related objects

Location
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
2045-2322
Extent
Online-Ressource
Language
Englisch
Notes
online resource.

Bibliographic citation
Microbiota Composition May Predict Anti-Tnf Alpha Response in Spondyloarthritis Patients: an Exploratory Study ; volume:8 ; number:1 ; day:3 ; month:4 ; year:2018 ; pages:1-11 ; date:12.2018
Scientific reports ; 8, Heft 1 (3.4.2018), 1-11, 12.2018

Creator
Bazin, Thomas
Contributor
Hooks, Katarzyna B.
Barnetche, Thomas
Truchetet, Marie-Elise
Enaud, Raphaël
Richez, Christophe
Dougados, Maxime
Hubert, Christophe
Barré, Aurélien
Nikolski, Macha
Schaeverbeke, Thierry
SpringerLink (Online service)

DOI
10.1038/s41598-018-23571-4
URN
urn:nbn:de:1111-201805288852
Rights
Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
15.08.2025, 7:32 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Bazin, Thomas
  • Hooks, Katarzyna B.
  • Barnetche, Thomas
  • Truchetet, Marie-Elise
  • Enaud, Raphaël
  • Richez, Christophe
  • Dougados, Maxime
  • Hubert, Christophe
  • Barré, Aurélien
  • Nikolski, Macha
  • Schaeverbeke, Thierry
  • SpringerLink (Online service)

Other Objects (12)

The immunogenicity to the first anti-TNF therapy determines the outcome of switching to a second anti-TNF therapy in spondyloarthritis patients

The immunogenicity to the first anti-TNF therapy determines the outcome of switching to a second anti-TNF therapy in spondyloarthritis patients

The effect of anti-TNF drugs on the intestinal microbiota in patients with spondyloarthritis, rheumatoid arthritis, and inflammatory bowel diseases

The effect of anti-TNF drugs on the intestinal microbiota in patients with spondyloarthritis, rheumatoid arthritis, and inflammatory bowel diseases

Monitoring of anti-TNF biological treatments

Monitoring of anti-TNF biological treatments

Access criteria for anti-TNF agents in spondyloarthritis: influence on comparative 1-year cost-effectiveness estimates

Access criteria for anti-TNF agents in spondyloarthritis: influence on comparative 1-year cost-effectiveness estimates

Stopping Anti-TNF in CD Remitters: Cons

Stopping Anti-TNF in CD Remitters: Cons

Development of anti-TNF antibody-gold nanoparticles (anti-TNF-AuNPs)

Development of anti-TNF antibody-gold nanoparticles (anti-TNF-AuNPs)

Anti-TNF, a magic bullet in cancer immunotherapy?

Anti-TNF, a magic bullet in cancer immunotherapy?

Combination of subtherapeutic anti-TNF dose with dasatinib restores clinical and molecular arthritogenic profiles better than standard anti-TNF treatment

Combination of subtherapeutic anti-TNF dose with dasatinib restores clinical and molecular arthritogenic profiles better than standard anti-TNF treatment

Is IL-6 an appropriate target to treat spondyloarthritis patients refractory to anti-TNF therapy? a multicentre retrospective observational study

Is IL-6 an appropriate target to treat spondyloarthritis patients refractory to anti-TNF therapy? a multicentre retrospective observational study

Predictors of response and anti-TNF drugs comparative efficacy

Predictors of response and anti-TNF drugs comparative efficacy

Tuberculosis in Juvenile Idiopathic arthritis under Anti-TNF therapy

Tuberculosis in Juvenile Idiopathic arthritis under Anti-TNF therapy

Predictive biomarkers for anti-TNF alpha therapy in IBD patients

Predictive biomarkers for anti-TNF alpha therapy in IBD patients

Related objects